KR20110074870A - 간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법 - Google Patents

간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법 Download PDF

Info

Publication number
KR20110074870A
KR20110074870A KR1020117008799A KR20117008799A KR20110074870A KR 20110074870 A KR20110074870 A KR 20110074870A KR 1020117008799 A KR1020117008799 A KR 1020117008799A KR 20117008799 A KR20117008799 A KR 20117008799A KR 20110074870 A KR20110074870 A KR 20110074870A
Authority
KR
South Korea
Prior art keywords
weeks
peginterferon
administered
ribavirin
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117008799A
Other languages
English (en)
Korean (ko)
Inventor
로버트 에스 카우프만
시릴 장 카미유 티튜
라몬 폴로
히스바이크 루돌프 피터 게르하르트 반
마리아 글로리아 부몬트
가스통 라파엘 피치오
Original Assignee
버텍스 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버텍스 파마슈티칼스 인코포레이티드 filed Critical 버텍스 파마슈티칼스 인코포레이티드
Publication of KR20110074870A publication Critical patent/KR20110074870A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117008799A 2008-09-24 2009-09-24 간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법 Withdrawn KR20110074870A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9984908P 2008-09-24 2008-09-24
US61/099,849 2008-09-24
US10965508P 2008-10-30 2008-10-30
US61/109,655 2008-10-30
US24304109P 2009-09-16 2009-09-16
US61/243,041 2009-09-16

Publications (1)

Publication Number Publication Date
KR20110074870A true KR20110074870A (ko) 2011-07-04

Family

ID=41396114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117008799A Withdrawn KR20110074870A (ko) 2008-09-24 2009-09-24 간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법

Country Status (11)

Country Link
US (2) US20110236351A1 (OSRAM)
EP (1) EP2328656A1 (OSRAM)
JP (1) JP2012503669A (OSRAM)
KR (1) KR20110074870A (OSRAM)
CN (1) CN102316935A (OSRAM)
AU (1) AU2009296653A1 (OSRAM)
CA (1) CA2738477A1 (OSRAM)
EA (1) EA201170484A1 (OSRAM)
IL (1) IL211810A0 (OSRAM)
MX (1) MX2011003121A (OSRAM)
WO (1) WO2010036799A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
CA2740728A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765283A4 (en) * 2004-06-08 2012-11-28 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
KR20090023360A (ko) * 2006-04-26 2009-03-04 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 감염 바이오마커
JP2010528013A (ja) * 2007-05-21 2010-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｖｘ−９５０を含む用量形態およびそれらの投与レジメン

Also Published As

Publication number Publication date
US20130101554A1 (en) 2013-04-25
US8871812B2 (en) 2014-10-28
IL211810A0 (en) 2011-06-30
US20110236351A1 (en) 2011-09-29
JP2012503669A (ja) 2012-02-09
MX2011003121A (es) 2011-04-21
CA2738477A1 (en) 2010-04-01
EP2328656A1 (en) 2011-06-08
AU2009296653A1 (en) 2010-04-01
WO2010036799A1 (en) 2010-04-01
CN102316935A (zh) 2012-01-11
EA201170484A1 (ru) 2012-03-30

Similar Documents

Publication Publication Date Title
US8431615B2 (en) Dose forms
US8871812B2 (en) Therapeutic regimen comprising PEG-interferon, ribavirin and VX-950 for the treatment of hepatitis
US20100189688A1 (en) Dose forms comprising VX-950 and their dosage regimen
US20140127160A1 (en) Treatment of hepatitis c virus with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interferon-alpha 2a/2b and ribavirin
HK1165739A (en) Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
HK1158507A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interferon-alpha-2a/2b and ribavirin
AU2012200942A1 (en) Dose forms comprising VX-950 and their dosage regimen
HK1148962A (en) Dose forms comprising vx-950 and their dosage regimen
HK1178451A (en) Dose forms comprising vx-950 and their dosage regimen

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110418

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20111006

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid